Lupin’s subsidiary Nanomi raises stake in MPPI to 99.89% after share acquisition

What Lupin announced

Lupin Limited filed a Regulation 30 disclosure on 1 July 2026 stating that its wholly‑owned Dutch subsidiary, Nanomi B.V., has completed the acquisition of 11,794,497 shares of Multicare Pharmaceuticals Philippines, Inc. (MPPI). In the same filing, MPPI confirmed the completion of a share buy‑back of 61,118 shares from two existing shareholders, with the remaining 30,559‑share buy‑back still underway. As a result, Nanomi’s holding in MPPI rose from 56.28% to 99.89% on the same day.

Acquisition of MPPI shares by Nanomi

Nanomi’s share purchase was first intimated to the exchanges on 1 April 2026 and reiterated on 29 May 2026. The definitive agreements covered the purchase of exactly 11,794,497 MPPI shares from certain existing shareholders, subject to customary closing conditions. The filing confirms that all conditions were satisfied and the transaction closed on 1 July 2026. No details of the purchase price, financing method, or any related party considerations were disclosed in the announcement.

MPPI share buy‑back

In a separate but related development, MPPI announced the completion of a buy‑back of 61,118 shares from two shareholders on 1 July 2026. This buy‑back was previously disclosed on 30 March 2026. The filing notes that the buy‑back of the balance 30,559 shares is still in progress, indicating that MPPI intends to consolidate its share capital further. The purpose of the buy‑back was not elaborated, nor were the terms (price per share, source of funds) disclosed.

Key facts at a glance

Why this matters for investors

The transactions substantially increase Lupin’s indirect control over MPPI, moving from a majority stake of 56.28% to near‑total ownership of 99.89%. Such consolidation can simplify group reporting, reduce minority‑interest adjustments, and potentially streamline strategic decisions for the Philippines‑based subsidiary. However, the filing does not disclose any immediate financial impact—no cash outflow, valuation, or earnings effect is mentioned. Investors should note that the buy‑back of the remaining 30,559 shares is still pending, which may affect MPPI’s share capital and future dividend policy once completed. The disclosure under Regulation 30 confirms that the company has complied with SEBI’s transparency requirements, and no further regulatory approvals appear to be pending for these specific transactions.

Conclusion

On 1 July 2026 Lupin’s subsidiary Nanomi finalized the purchase of 11.79 million MPPI shares, raising its stake to 99.89%. Simultaneously, MPPI completed a buy‑back of 61,118 shares, with the remainder still in process. While the filing provides clear numbers on share counts and ownership percentages, it does not reveal the financial terms of the deals. The consolidation enhances Lupin’s control over MPPI, and the remaining buy‑back will be completed in due course.